Core Scientific Inc. stocks have been trading down by -9.64 percent amid bearish sentiment surrounding bitcoin mining profitability and regulation.
Click Here for a Millionaire's POV on Trading CORZ
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Keefe Bruyette downgraded Core Scientific from Outperform to Market Perform and cut its price target to $25 from $28, flagging higher execution risk in 2H 2026.
- The firm now sees Core Scientific as fairly valued around $25, removing a key bullish support for CORZ.
- Core Scientific posted a Q2 net loss of $3.32 per share versus expectations for a $0.06 loss, a massive earnings miss.
- Chief Legal and Administrative Officer Todd M. Duchene sold 10,000 shares (about $262K) on 2026/06/29 but still holds roughly 2.04 million CORZ shares.
Live Update At 12:32:06 EDT: On Wednesday, July 29, 2026 Core Scientific Inc. stock [NASDAQ: CORZ] is trending down by -9.64%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
CORZ is trading like a name in repricing mode. Over the past couple of weeks, Core Scientific has slid from closes above $24 on 2026/07/21 to about $18.75 most recently, a pullback of roughly 20%. That drop lines up with a brutal Q2 print and a fresh analyst downgrade, and traders are clearly reassessing risk.
On the daily chart, CORZ shows a clear lower-high, lower-low pattern after topping near $24–$25. Each bounce has been sold, with failed pushes around $23–$24 on 2026/07/23 and 2026/07/24, then heavier selling after earnings. Intraday, the 5‑minute tape shows a steady bleed from the $21 open down into the high‑$18s, suggesting controlled but persistent selling pressure rather than a quick flush and bounce.
More Breaking News
- WULF Stock Under Pressure As New York Data Center Moratorium Hits AI Hype
- STFS Stock Slides As Volatility Grips Thinly Traded Fashion IPO
- GMM Stock Whipsaws As Global Mofy AI Funnels Cash Into Growth
- ITRI Stock Jumps As Traders Eye Q2 Earnings Call
Under the hood, Core Scientific’s fundamentals are ugly. Q2 revenue was about $164.2M, but the company still booked a net loss of roughly $1.16B, or $3.32 per share. Margins are deeply negative, with EBIT margin around ‑335% and profit margin worse than ‑300%. CORZ carries heavy long‑term debt of about $4.30B, negative equity near ‑$2.42B, and a current ratio below 1, signaling balance sheet stress. For short‑term traders, that mix supports volatility and sharp sentiment swings around every new headline.
Why Traders Are Watching CORZ Now
CORZ is back on every active trader’s screen because the story just shifted from “growth and scale” to “can they execute without blowing up.” The Q2 earnings miss from Core Scientific was not a small wobble; it was a full‑on derailment versus expectations. The Street looked for a tiny $0.06 loss per share. CORZ came in at a $3.32 loss instead. That kind of gap forces funds and fast money to reprice overnight.
Right after that, Keefe Bruyette moved from Outperform to Market Perform on Core Scientific and cut the price target from $28 to $25. The firm called out elevated execution risk in the back half of 2026 and argued that the CORZ share price was running above its estimate of equity value once you factor in the lease portfolio and net debt. Translation for traders: one of the bulls just stepped back and is now saying, “The easy upside is gone.”
On the tape, you can see that rethink in real time. CORZ has broken its recent support levels and is now trading several dollars below the new $25 target. That gives traders a clearer map: rallies into the low‑$20s are now suspect unless new positive catalysts show up, while any cracks under the high‑$18s can trigger momentum selling and possible panic.
Insider activity adds another subplot. Todd M. Duchene, Core Scientific’s Chief Legal and Administrative Officer, sold 10,000 CORZ shares on 2026/06/29 for about $262K. On its own, that’s tiny next to his remaining 2.04 million‑share stake, which makes it look more like routine trimming than a fire alarm. But in a name like CORZ, already dealing with a huge loss and a downgrade, traders often treat any insider selling as one more reason to tighten risk.
In short, Core Scientific has shifted into a classic “show me” phase. That kind of setup can be deadly for buy‑and‑hold, but it can be a playground for disciplined momentum and short‑term trading.
Conclusion
For active traders, CORZ right now is all about managing risk around a broken expectations story. Core Scientific delivered a staggering Q2 loss, is burning cash, and sits on heavy debt with negative equity. Keefe Bruyette’s downgrade to Market Perform and the new $25 price target tell you plain and simple that at least one core bull no longer sees clear upside from here without serious execution improvements.
Technically, Core Scientific has lost its uptrend and is testing a new range in the high teens. That’s where traders need to stay laser‑focused on price action. If CORZ starts to base and hold above recent lows on rising volume, you can get sharp oversold bounces. If it cracks support with size hitting the bid, you can also see fast trend‑down days. Either way, the stock is giving clean levels to trade against.
Insider selling from Todd Duchene looks modest compared with his remaining CORZ stake, but when sentiment is fragile, traders often assume “guilty until proven innocent” on any negative data point. That’s why risk control matters more than opinions here. As Tim Bohen, lead trainer with StocksToTrade says, “The best trades are the ones you can make without emotion. Plan it, then execute it as if it’s routine.” In a name like CORZ, that kind of disciplined, rules‑based execution can be the difference between a controlled loss and a catastrophic one when headlines hit.
Tim Sykes drills this into students all the time: “Patterns repeat, but only if you live to trade another day by cutting losses quickly.” Core Scientific is a live example. CORZ offers opportunity, but only for traders who respect volatility, keep position sizes in check, and treat every bounce or breakdown as a trade — not a promise.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.